RIPK3 and cancer: Since most of the prognostic information from the previous studies was in patients that may have received chemotherapy (Colbert et al., 2013, Conev et al., 2019, Ertao et al., 2016, Feng et al., 2015, Koo et al., 2015, Lin et al., 2023, Nicole et al., 2022), it would logically follow that patients with high RIPK3 levels would respond better to killing cancer cells, and also, as mentioned in the fourth hypothesis above, contributing to immunogenic cell death.